Helen X. Chen, M.D.

Dr. Helen Chen joined NCI’s Cancer Therapy Evaluation Program (CTEP) in 2000. She currently serves as Associate Chief of Immuno-oncology for the Investigational Drug Branch (IDB), leading activities related to the clinical development of new cancer immunotherapy agents and therapeutic antibodies. Dr. Chen is board-certified in Medical Oncology after completing her Fellowship training at Georgetown University Medical Center in Washington D.C.